These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin. van der Meijden AP; Steerenberg PA; van Hoogstraaten IM; Kerckhaert JA; Schreinemachers LM; Harthoorn-Lasthuizen EJ; Hagenaars AM; de Jong WH; Debruijne FM; Ruitenberg EJ Cancer Immunol Immunother; 1989; 28(4):287-95. PubMed ID: 2784716 [TBL] [Abstract][Full Text] [Related]
5. Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer. Gan YH; Zhang Y; Khoo HE; Esuvaranathan K Eur J Cancer; 1999 Jul; 35(7):1123-9. PubMed ID: 10533458 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells. Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930 [TBL] [Abstract][Full Text] [Related]
7. Analysis of local T lymphocyte subsets upon stimulation with intravesical BCG: a model to study tuberculosis immunity. Ponticiello A; Perna F; Maione S; Stradolini M; Testa G; Terrazzano G; Ruggiero G; Malerba M; Sanduzzi A Respir Med; 2004 Jun; 98(6):509-14. PubMed ID: 15191035 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of local immune response after intravesical bacille Calmette-Guérin treatment for superficial bladder cancer. Patard JJ; Muscatelli-Groux B; Saint F; Popov Z; Maille P; Abbou C; Chopin D Br J Urol; 1996 Nov; 78(5):709-14. PubMed ID: 8976765 [TBL] [Abstract][Full Text] [Related]
9. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341 [TBL] [Abstract][Full Text] [Related]
10. Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma. Boccafoschi C; Montefiore F; Pavesi M; Pastormerlo M; Annoscia S; Lozzi C; Betta PG Eur Urol; 1992; 21(4):304-8. PubMed ID: 1459153 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms. Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831 [TBL] [Abstract][Full Text] [Related]
12. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients. Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of cellular immunity following bacillus Calmette-Guérin therapy in patients with superficial bladder cancer. Sarica K; Baltaci S; Bedük Y; Süzer O; Kiliç S; Müftüğlu YZ; Göğüş O Urol Int; 1995; 54(3):137-41. PubMed ID: 7604454 [TBL] [Abstract][Full Text] [Related]
15. Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin. Liu X; Dowell AC; Patel P; Viney RP; Foster MC; Porfiri E; James ND; Bryan RT Future Oncol; 2014 Jun; 10(8):1443-56. PubMed ID: 25052754 [TBL] [Abstract][Full Text] [Related]
16. Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy. Chevalier MF; Schneider AK; Cesson V; Dartiguenave F; Lucca I; Jichlinski P; Nardelli-Haefliger D; Derré L Eur Urol; 2018 Nov; 74(5):540-544. PubMed ID: 30033046 [TBL] [Abstract][Full Text] [Related]
17. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. Ratliff TL; Gillen D; Catalona WJ J Urol; 1987 Jan; 137(1):155-8. PubMed ID: 3491909 [TBL] [Abstract][Full Text] [Related]
19. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway. Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321 [TBL] [Abstract][Full Text] [Related]
20. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. Böhle A; Gerdes J; Ulmer AJ; Hofstetter AG; Flad HD J Urol; 1990 Jul; 144(1):53-8. PubMed ID: 2359181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]